# 2026-20075: FDA blesses room-temp goo for storing your blood vessels?

2026-20075, Medical Devices; Gastroenterology-Urology Devices; Classification of the Flushing and Storage Solution for Vascular Autografts at Room Temperature, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2026-09-30, effective 2026-09-30; PRIA reads it as touching household money (as of 2026-10-07).

- Canonical: https://policyrisk.com/federal-register/2026-20075
- As of: 2026-10-07
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-20075
- Title: Medical Devices; Gastroenterology-Urology Devices; Classification of the Flushing and Storage Solution for Vascular Autografts at Room Temperature
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 61703
- Published: 2026-09-30
- Effective: 2026-09-30
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-07

## In one line

FDA blesses room-temp goo for storing your blood vessels?

## Summary

The FDA is officially putting the flushing and storage solution for vascular autografts at room temperature into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps companies bring these devices to patients faster and safer, starting from September 30, 2026, with the classification effective since October 4, 2023. Medical device makers and patients will benefit from easier access to these important solutions without extra costs or delays.

## Abstract

The Food and Drug Administration (FDA) is classifying the flushing and storage solution for vascular autografts at room temperature into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the flushing and storage solution for vascular autografts at room temperature. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Patients gain faster access to device: benefit, medium. The FDA classified the flushing and storage solution for vascular autografts at room temperature into Class II with special controls, a change FDA says will enhance patients' access to beneficial innovation by reducing regulatory burdens. The final order is effective September 30, 2026, and the cla…
- Easier regulatory path for device makers: mixed, medium. FDA's De Novo classification lets this device be Class II and serve as a predicate for future devices, allowing other sponsors to use the 510(k) pathway instead of premarket approval. The classification was made applicable on October 4, 2023 and the order is effective September 30, 2026.
- New testing and labeling requirements for makers: cost, medium. Manufacturers must meet the special controls: clinical data evaluating adverse events (for coronary artery bypass graft indications this must include incidence of major adverse cardiac events, vein graft occlusion, and mortality); non-clinical performance testing (including maintenance of cell viab…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-20075 on federalregister.gov](https://www.federalregister.gov/documents/2026/09/30/2026-20075/medical-devices-gastroenterology-urology-devices-classification-of-the-flushing-and-storage-solution)
- [2026-20075 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-09-30/pdf/2026-20075.pdf)

## Related
- [Previous: 2026-20067, Medicare Program; FY 2027 Hospice Wage Index and Payment Rate Update and Hospic…](https://policyrisk.com/federal-register/2026-20067)
- [Next: 2026-20082, International Traffic in Arms Regulations: Syria Country Policy Revision](https://policyrisk.com/federal-register/2026-20082)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-20075 (as of 2026-10-07).
